论文部分内容阅读
目的 探讨苦参碱和拉米夫定治疗活动性肝硬化的临床疗效。方法 随机选择 15 1例活动性肝硬化患者 ,治疗组 63例 ,苦参碱 2 0 0mg ,静脉滴注 ,qd ,8wk为 1疗程 ;拉米夫定 0 . 1,qd ,疗程 1年 ,产生应答者继续服用药物半年。各组在性别、年龄、病程及疾病轻重等方面皆具可比性。观察治疗前后肝功、肝纤维化指标及 1、3、6、12个月的HBV DNA变化。结果 苦参碱和拉米夫定治疗组与对照组比较肝功能、肝纤维化指标下降 ,HBV DNA的阴转率增加 ,经统计学处理有显著性差异 (P <0 . 0 5 )。结论 苦参碱和拉米夫定治疗活动性肝硬化有明显的临床疗效。是抗病毒、抗肝纤维化的有效药物。
Objective To investigate the clinical efficacy of matrine and lamivudine in the treatment of active cirrhosis. Methods A total of 151 patients with active cirrhosis were randomly divided into treatment group (63 cases), matrine (200 mg), intravenous drip, qd, 8wk for 1 course of treatment, lamivudine 0.1, qd for 1 year Respondents continued to take drugs for six months. Each group in gender, age, duration and severity of disease are comparable. The changes of liver function and liver fibrosis before and after treatment and the changes of HBV DNA at 1, 3, 6 and 12 months were observed. Results Matrine and lamivudine treatment group compared with the control group decreased liver function, liver fibrosis index, HBV DNA negative conversion rate increased statistically significant (P <0.05). Conclusion Matrine and lamivudine have obvious clinical curative effect in the treatment of active cirrhosis. Is antiviral, anti-liver fibrosis effective drugs.